Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Dravet Syndrome: Drug Development Pipeline Study, H1 2018 -

Research and Markets
Posted on: 02 Mar 18

The "Dravet Syndrome: Drug Development Pipeline Study, H1 2018" report has been added to's offering.

The most comprehensive pipeline review Dravet Syndrome - Drug Development Pipeline Study provides in-depth analysis and update information on Dravet Syndrome pipeline drugs. Current status of all the drugs in the Dravet Syndrome pipeline is provided in the research work.

Previously known as severe myoclonic epilepsy of infancy (SMEI), the neurological disease is attracting wide interest from pharmaceutical companies over the past five years. In particular, with 10 drugs receiving orphan drug status, the prominence of Dravet Syndrome pipeline is robust.

The report provides detailed analysis of Dravet Syndrome pipeline including companies involved, drugs in different stages of development, drug development details across regions (North America, Europe, Asia Pacific and Rest of the World). Furthermore, the Dravet Syndrome report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Dravet Syndrome industry.


  • All latest industry developments and their impact on projects and companies
  • Complete overview of global Dravet Syndrome therapy options and treatments
  • The pipeline study reviews drug details for Dravet Syndrome by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA) and molecule
  • Mergers, Acquisitions, licensing, co-development and project acquisition news for Dravet Syndrome market
  • Dravet Syndrome drugs being developed in combination with other drugs are also detailed
  • Company wise drugs listed

Products Mentioned:

  • AntagoNAT
  • Ataluren (Translarna)
  • BIS-001
  • Clobazam
  • Epidiolex
  • EPX 100
  • EPX 200
  • EPX 300
  • Nav1.6 sodium channel
  • PRAX 330
  • SAGE-217
  • SGE-516
  • Synthetic cannabidiol
  • TAK 935
  • ZX-008

Companies Mentioned

  • Biscayne Pharmaceuticals
  • Brabant Pharma Limited
  • California Pacific Medical Center
  • Epygenix Therapeutics
  • GW Pharmaceuticals; University of Alabama; University of Utah
  • Harvard University
  • INSYS Therapeutics Inc
  • Lundbeck Inc
  • Northwestern University Feinberg School of Medicine; Praxis Precision Medicines
  • OPKO Health Inc
  • OVATION Pharmaceuticals
  • Ovid Therapeutics; Takeda
  • PTC Therapeutics; Sanofi Genzyme
  • Sage Therapeutics Inc
  • The University of Montreal Hospital Research Center; University of Chicago
  • University of California; University of Colorado
  • Xenon Pharmaceuticals Inc
  • Zogenix Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 02/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.